16 July 2015 in Alimentary Pharmacology & Therapeutics
Summary: Background: Proton pump inhibitors (PPIs) have a well‐established safety profile. However, concerns have been raised about a potential relationship betweenPPI‐induced hypergastrinaemia and the development of enterochromaffin‐like (ECL) cell hyperplasia, neuroendocrine tumours and gastric cancer during long‐term therapy.Aim: To review the effects of long‐termPPIuse on serum gastrin levels and gastric histopathology.Methods: A systematic literature search was conducted in PubMed on 21 April 2015 to identify studies reporting the effects of long‐term (defined as >3 years)PPIuse on gastrin levels and gastric histopathology.Results: A total of 16 studies (1920 patients) met the inclusion criteria. During long‐termPPItherapy, mean gastrin levels rose to one to three times the upper limit of the normal range (~100 pg/mL), and an increased prevalence ofECLcell hyperplasia was observed (+7.8–52.0%).Helicobacter pylori‐positive patients had a significantly increased risk of developingECLlinear/micronodular hyperplasia compared withH. pylori‐negative patients [OR: 2.45 (95%CI: 1.47–4.10),P = 0.0006]; however, no evidence of neoplastic changes was found. The risk of corpus atrophy was markedly higher inH. pylori‐positive patients than inH. pylori‐negative patients [OR: 11.45 (95%CI: 6.25–20.99),P < 0.00001]. Not a single case of gastric adenocarcinoma was found.Conclusions: Long‐termPPItherapy induced moderate hypergastrinaemia in most patients and an increased prevalence ofECLcell hyperplasia.H. pylori‐positive patients receiving long‐termPPItherapy were exposed to a higher risk of corpus atrophy thanH. pylori‐negative patients. No neuroendocrine tumours or gastric cancers were found.
29 January 2007 in British Journal of Surgery
1 December 2009 in Clinical Gastroenterology and Hepatology
NGNordic GERD Study Group
+6
13 October 2015 in Alimentary Pharmacology & Therapeutics
14 February 2006 in Alimentary Pharmacology & Therapeutics
TGTHE NORDIC GERD STUDY GROUP
THE NORDIC GERD STUDY GROUP
+7